Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
thrombosis/protease
Veza se sprema u međuspremnik
Stranica 1 iz 88 rezultatima
Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 35 U.S.C. .sctn.371 U.S. national stage filing from PCT Application Ser. No. PCT/JP2004/019226 having an international filing date of Dec. 22, 2004, published under WO 2005/062054 A1 on Jul. 7, 2005, which claims priority to Japanese
Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The invention relates to mutants of factor VII-activating protease (FSAP) and to reduced blood plasma levels of FSAP as indicators of an increased risk for the development and progression of atherothrombosis (or arterial thrombosis) and of the pathophysiological sequelae resulting
Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The invention relates to mutants of factor VII-activating protease (FSAP) and to reduced blood plasma levels of FSAP as indicators of an increased risk for the development and progression of atherothrombosis (or arterial thrombosis) and of the pathophysiological sequelae resulting
Fibrinogenolytic proteases with thrombolytic and antihypertensive activities: medical application and novel process of expression and production
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the purification and use of a novel family of fibrinogenolytic proteases. Specifically, this invention relates to a fibrinogenolytic protease which possesses a strong beta-fibrinogenolytic activity and does not cause
Protease resistant urokinase
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND
Urokinase (E.C. 3.4.21.31) is a serine protease which activates plasminogen to plasmin. The protein is synthesized in a variety of tissues including endothelium and kidney, and is excreted in trace amounts into urine. Purified urokinase exists in two active forms, a high molecular weight
Protease-activated receptor 3 and uses thereof
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
FIELD OF THE INVENTION
This invention relates to nucleic acids, their encoded protease-activated receptor 3 proteins, and screening assays for agonists and antagonists of the protease activated receptor 3 proteins.
BACKGROUND OF THE INVENTION
Thrombin, a coagulation protease generated at sites of
DNA encoding a protease-activated receptor 3
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
FIELD OF THE INVENTION
This invention relates to nucleic acids, their encoded protease-activated receptor 3 proteins, and screening assays for agonists and antagonists of the protease activated receptor 3 proteins.
BACKGROUND OF THE INVENTION
Thrombin, a coagulation protease generated at sites of
Immunoassays for catalytically-active, serine proteases
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND
Thrombosis and thrombolysis are maintained in delicate balance by a series of high regulated enzymatic reactions. The component enzymes are are largely serine proteases which are produced as needed from zymogens, inactive forms of the enzymes which circulate in the blood at relatively
DNA encoding the human serine protease EOS
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND OF THE INVENTION
Members of the trypsin/chymotrypsin-like (S1) serine protease family play pivotal roles in a multitude of diverse physiological processes, including digestive processes and regulatory amplification cascades through the proteolytic activation of inactive zymogen
Antibody immunologically reactive with serine protease EOS
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND OF THE INVENTION
Members of the trypsin/chymotrypsin-like (S1) serine protease family play pivotal roles in a multitude of diverse physiological processes, including digestive processes and regulatory amplification cascades through the proteolytic activation of inactive zymogen
DNA encoding the human serine protease EOS
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND OF THE INVENTION
Members of the trypsin/chymotrypsin-like (S1) serine protease family play pivotal roles in a multitude of diverse physiological processes, including digestive processes and regulatory amplification cascades through the proteolytic activation of inactive zymogen
Methods for Identifying modulators of serine protease EOS
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND OF THE INVENTION
Members of the trypsin/chymotrypsin-like (S1) serine protease family play pivotal roles in a multitude of diverse physiological processes, including digestive processes and regulatory amplification cascades through the proteolytic activation of inactive zymogen
System and method for delivering protease inhibitors
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
BACKGROUND
1. Technical Field
The present invention generally relates to a system and a method for delaying the dissolution of blood clots, and more particularly, the present invention provides a method and a delivery system for a material which delays the degradation of fibrin based blood clots.
2.
Mast cell protease that cleaves fibrinogen
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
FIELD OF THE INVENTION
This invention relates to compositions containing a mast cell protease and its derivatives, and methods for use thereof. The mast cell protease selectively cleaves fibrinogen in vitro and in vivo. Accordingly, the compositions of the invention are useful for modulating fibrin
Therapeutic application of Kazal-type serine protease inhibitors
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
This is a national stage entry of PCT/EP2008/001009, filed Feb. 11, 2008, which claims priority to EP 07002903.8, filed Feb. 12, 2007, all of which are incorporated herein by reference.
The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
- Radi na 55 jezika
- Biljni lijekovi potpomognuti znanošću
- Prepoznavanje bilja slikom
- Interaktivna GPS karta - označite bilje na mjestu (uskoro)
- Pročitajte znanstvene publikacije povezane s vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima
